Analysis: Trump's drug pricing policy is a significant blow to pharmaceutical companies.

Analysts at Bryan Garnier Research stated in a report that although it is uncertain whether Trump's "most favored nation" drug pricing policy will receive enough political support in Congress, this policy poses a threat to the pharmaceutical industry. Analysts said that Trump had introduced a similar policy during his first term in 2020, but it was blocked by a federal judge and ultimately revoked by President Biden in 2021. They said it is still unclear which aspects of medical insurance would be affected if this policy were to take effect.